Member Info for jayblu48

feels about his purchase at 3.5

won the Best Technology Award at last nights European Mediscience Award

you are so obvious it is getting embaraasing

is helping chemists discover new life-enhancing drugs http://www.wired.co.uk/article/using-vr-to-discover-new-life-saving-drugs

I doubt it wil take £12M in buys to double the price, the MMs will shoot this up at the slightest sign of good buying

it gives SC a nice average down price, and it looks like this is the bottom

surprised he had time to write as normally too busy pumping OBC

what was your name when you told us several months ago as you only have 1 post

never expected to be able to top up at 2.41, thanks TB

more chance of hitting 10 than 5, people will miss the boat if they are waiting for such a low buy in price

on June 5th BMD tweeted he was holding, a few Tweets later he wrote he had sold some, cannot be trusted

the buys are at 0.147 and showing as sells, not much going on either way

this RNS is for Block Commodities which should be under BLCC, this mistake happens quite often!

and will buy more over the next few days as it is hard to work out when our seller will finish so hopefully will get a good average price, certainly seems great value at these levels and there are other buyers around. Shouldn't be too long to go before he clears his position.

MMs drop the price but can't buy any, it goes to 2.4 NT

Oct 2015 - In the Company's Admission document and in previous results announcements the Company indicated it was preparing to make a 510(k) submission for TexRAD to be used as an analytical tool for measuring texture in CT scans. The Company now recognises that there are significant commercial opportunities available to Feedback if TexRAD is used in conjunction with other imaging biomarkers to create integrated products for specific clinical applications. The Board expects these types of products to be marketed much more effectively to clinicians compared with a general software application. As part of the updated strategy the Company is also considering prioritising CE marking in order to accelerate development of commercial products for the European markets. As a consequence of this new focus, FDA approval for TexRAD is no longer regarded as one of the Company's principal corporate objectives. Feedback has sold research versions of TexRAD software to many of the world's leading oncology research centres. In conjunction with this, pioneering research is being undertaken in these centres to evaluate how texture analysis can be introduced into radiology workflow to assist clinicians in the assessment and patient management of various different types of cancer. Feedback is now at the stage where the publication of research findings is likely to have a significant effect on determining where the Company should be concentrating its efforts. As a result of the changes highlighted above the Company has concluded that it no longer has a compelling strategic need to continue the sale of research versions of TexRAD to a broad market and intends to restrict further sales of the research versions of TexRAD to a limited number of new customers. The Company's future strategy is expected to involve the formation of more joint ventures and collaborations where Feedback's valuable intellectual property can be combined with the specialist skills and intellectual property of other companies and research institutions. By adopting this approach the Company is expected to generate licensing and royalty revenue streams and a residual equity participation in these joint ventures.

a reasonable spread between the buy and sell price, maybe the MMs have got their books straight ahead of the new tax year

sellers who bought last week and want instant gratification, whilst buyers are probably waiting until the new tax year, might be tempted to top up before then if the price falls much further

you could be right, but I feel any weakness in price will be bought in to. "With the Indivior agreement providing the first validation of its approach, Dix said C4X is ready to crank the handle, and he expects to conclude another deal in the next year. There are eight programs in the portfolio currently, in indications including diabetes, psoriasis and chronic obstructive pulmonary disorder. "

The charts could be wrong re resistance as whilst Canadian holders may have been selling over the last few days many investors in UK have not been able to take advantage of low prices as they could not buy through their UK brokers. Tomorrow should be very interesting.